Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin

Jung,Sunyoung; Ro,Simon   Weonsang; Jung,Geunyoung; Ju,Hye-Lim; Yu,Eun-Sil; Son,Woo-Chan

doi:10.3892/or.2013.2264

Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin

Authors:
- Sunyoung Jung
- Simon Weonsang Ro
- Geunyoung Jung
- Hye-Lim Ju
- Eun-Sil Yu
- Woo-Chan Son
View Affiliations

Affiliations: Asan Institute for Life Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea, Liver Cirrhosis Clinical Research Center, Yonsei University, College of Medicine, Seoul, Republic of Korea, Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
Published online on: January 31, 2013 https://doi.org/10.3892/or.2013.2264
Pages: 1293-1298
Copyright: © Jung et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Sleeping Beauty transposon system is used as a tool for insertional mutagenesis and oncogenesis. However, little is known about the exact histological phenotype of the tumors induced. Thus, we used immunohistochemical markers to enable histological identification of the type of tumor induced by subcutaneous injection of the HRAS, c-Myc and shp53 oncogenes in female C57BL/6 mice. The tumor was removed when it reached 100 mm3 in volume. Subsequently, we used 13 immunohistochemical markers to histologically identify the tumor type. The results suggested that the morphology of the tumor was similar to that of sarcomatoid carcinoma.

View Figures

View References

1	Belur LR, Podetz-Pedersen KM, Sorenson BS, Hsu AH, Parker JB, Carlson CS, Saltzman DA, Ramakrishnan S and McIvor RS: Inhibition of angiogenesis and suppression of colorectal cancer metastatic to the liver using the Sleeping Beauty Transposon System. Mol Cancer. 10:142011. View Article : Google Scholar : PubMed/NCBI
2	Howell VM: Sleeping beauty-a mouse model for all cancers? Cancer Lett. 317:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
3	Song JS, Kim HP and Rubin E: Development of a Sleeping Beauty-based telomerase gene delivery system for hepatocytes. Biosci Biotechnol Biochem. 75:227–231. 2011. View Article : Google Scholar : PubMed/NCBI
4	Carlson CM, Frandsen JL, Kirchhof N, McIvor RS and Largaespada DA: Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci USA. 102:17059–17064. 2005. View Article : Google Scholar : PubMed/NCBI
5	Kim IS and Baek SH: Mouse models for breast cancer metastasis. Biochem Biophys Res Commun. 394:443–447. 2010. View Article : Google Scholar : PubMed/NCBI
6	Thyagarajan T, Totey S, Danton MJ and Kulkarni AB: Genetically altered mouse models: the good, the bad and the ugly. Crit Rev Oral Biol Med. 14:154–174. 2003. View Article : Google Scholar : PubMed/NCBI
7	Rivera J and Tessarollo L: Genetic background and the dilemma of translating mouse studies to humans. Immunity. 28:1–4. 2008. View Article : Google Scholar : PubMed/NCBI
8	Radiloff DR, Rinella ES and Threadgill DW: Modeling cancer patient populations in mice: complex genetic and environmental factors. Drug Discov Today Dis Models. 4:83–88. 2008. View Article : Google Scholar : PubMed/NCBI
9	Andrechek ER and Nevins JR: Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med. 88:1095–1100. 2010. View Article : Google Scholar : PubMed/NCBI
10	Dupuy AJ: Transposon-based screens for cancer gene discovery in mouse models. Semin Cancer Biol. 20:261–268. 2010. View Article : Google Scholar : PubMed/NCBI
11	Lassman AB, Dai C, Fuller GN, Vickers AJ and Holland EC: Overexpression of c-Myc promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice. Neuron Glia Biol. 1:157–163. 2004. View Article : Google Scholar : PubMed/NCBI
12	Ishii HH, Gobe GC, Pan W, Yoneyama J and Ebihara Y: Apoptosis and cell proliferation in the development of gastric carcinomas: associations with c-myc and p53 protein expression. J Gastroenterol Hepatol. 17:966–972. 2002. View Article : Google Scholar : PubMed/NCBI
13	Yeilding NM, Procopio WN, Rehman MT and Lee WM: c-myc mRNA is down-regulated during myogenic differentiation by accelerated decay that depends on translation of regulatory coding elements. J Biol Chem. 273:15749–15757. 1998. View Article : Google Scholar : PubMed/NCBI
14	Schneider MD, Perryman MB, Payne PA, Spizz G, Roberts R and Olson EN: Autonomous expression of c-myc in BC3H1 cells partially inhibits but does not prevent myogenic differentiation. Mol Cell Biol. 7:1973–1977. 1987.PubMed/NCBI
15	Aldaz CM, Gollahon LS and Chen A: Systematic HRAS amplification in ovary-independent mammary tumors: correlation with progressively anaplastic phenotypes. Cancer Res. 53:5339–5344. 1993.PubMed/NCBI
16	Hill R, Song Y, Cardiff RD and Van Dyke T: Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell. 123:1001–1011. 2005. View Article : Google Scholar : PubMed/NCBI
17	Keng VW, Villanueva A, Chiang DY, et al: A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma. Nat Biotechnol. 27:264–274. 2009. View Article : Google Scholar : PubMed/NCBI
18	Goryshin IY, Jendrisak J, Hoffman LM, Meis R and Reznikoff WS: Insertional transposon mutagenesis by electroporation of released Tn5 transposition complexes. Nat Biotechnol. 18:97–100. 2000. View Article : Google Scholar : PubMed/NCBI